Susquehanna International Group, LLP Enlivex Therapeutics Ltd. Transaction History
Susquehanna International Group, LLP
- $823 Billion
- Q3 2025
A detailed history of Susquehanna International Group, LLP transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 54,850 shares of ENLV stock, worth $53,753. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,850Holding current value
$53,753% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding ENLV
# of Institutions
32Shares Held
930KCall Options Held
0Put Options Held
0-
Citizens Financial Group Inc231KShares$226,7950.0% of portfolio
-
Morgan Stanley New York, NY174KShares$170,1520.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny157KShares$154,1460.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il68.9KShares$67,5570.0% of portfolio
-
Xtx Topco LTD London, X042.7KShares$41,8140.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $18M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...